Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer
NCT01874353Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2013
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of olaparib in ovarian cancer, sponsored by AstraZeneca. Started Sep 2013; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01874353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01874353.